Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevun...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

TylerDurd3n Sep. 8 at 5:38 PM

$STOK My favorite stock for 2 months, this thing slays!!! WOW don’t watch this stock we’re doing fine lmao

0 · Reply

Morty752 Sep. 8 at 2:45 PM

$STOK Almost there 💰💰💰

0 · Reply

LadsAndGents Sep. 6 at 2:33 AM

$STOK good luck all.. I am all out.. was holding since $8 started selling from 12.5 and finally all out today $XBI

0 · Reply

TylerDurd3n Sep. 5 at 10:59 PM

$STOK

0 · Reply

Morty752 Sep. 5 at 7:39 PM

$STOK This has just started

0 · Reply

Morty752 Sep. 5 at 7:21 PM

$STOK People have shorted this. My stocks are loaned on my account. 😐

0 · Reply

kshonstocks Sep. 5 at 5:32 PM

$STOK rs new high list

0 · Reply

Morty752 Sep. 5 at 1:39 PM

$STOK I like this ticker

0 · Reply

TylerDurd3n Sep. 4 at 4:39 PM

$STOK

0 · Reply

Morty752 Sep. 4 at 2:04 PM

$STOK Someone should stop the insiders from selling their shares 😂

0 · Reply

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

Aug 28, 2025, 4:30 PM EDT - 17 days ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 25, 2025, 7:00 AM EDT - 20 days ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

Aug 18, 2025, 4:30 PM EDT - 27 days ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aug 12, 2025, 4:01 PM EDT - 4 weeks ago

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 11, 2025, 7:00 AM EDT - 4 weeks ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BIIB

Aug 7, 2025, 7:00 AM EDT - 5 weeks ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Aug 6, 2025, 4:30 PM EDT - 5 weeks ago

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 4:30 PM EDT - 2 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jul 10, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jun 15, 2025, 11:27 PM EDT - 3 months ago

Stoke Therapeutics: Impressive Pipeline And Big Backers

May 29, 2025, 7:30 AM EDT - 3 months ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 4 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 4:30 PM EDT - 5 months ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 18, 2025, 12:56 PM EDT - 6 months ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 7:00 AM EDT - 6 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 6:58 AM EDT - 6 months ago

Stoke Therapeutics Announces CEO Transition

Feb 26, 2025, 4:30 PM EST - 7 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Feb 18, 2025, 8:46 AM EST - 7 months ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

BIIB

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Feb 18, 2025, 8:00 AM EST - 7 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

BIIB

Feb 16, 2025, 2:23 PM EST - 7 months ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Jan 8, 2025, 4:30 PM EST - 8 months ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 8 months ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 8 months ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 10 months ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 10 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 10 months ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 10 months ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 11 months ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 1 year ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI XAIR

Jun 14, 2024, 12:10 PM EDT - 1 year ago

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 6, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 11:40 PM EDT - 1 year ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Mar 26, 2024, 4:07 PM EDT - 1 year ago

Stoke Therapeutics Announces Proposed Public Offering

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 8, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Jan 4, 2024, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TylerDurd3n Sep. 8 at 5:38 PM

$STOK My favorite stock for 2 months, this thing slays!!! WOW don’t watch this stock we’re doing fine lmao

0 · Reply

Morty752 Sep. 8 at 2:45 PM

$STOK Almost there 💰💰💰

0 · Reply

LadsAndGents Sep. 6 at 2:33 AM

$STOK good luck all.. I am all out.. was holding since $8 started selling from 12.5 and finally all out today $XBI

0 · Reply

TylerDurd3n Sep. 5 at 10:59 PM

$STOK

0 · Reply

Morty752 Sep. 5 at 7:39 PM

$STOK This has just started

0 · Reply

Morty752 Sep. 5 at 7:21 PM

$STOK People have shorted this. My stocks are loaned on my account. 😐

0 · Reply

kshonstocks Sep. 5 at 5:32 PM

$STOK rs new high list

0 · Reply

Morty752 Sep. 5 at 1:39 PM

$STOK I like this ticker

0 · Reply

TylerDurd3n Sep. 4 at 4:39 PM

$STOK

0 · Reply

Morty752 Sep. 4 at 2:04 PM

$STOK Someone should stop the insiders from selling their shares 😂

0 · Reply

Morty752 Sep. 2 at 2:03 PM

$STOK Next target will be $23.

0 · Reply

JojoABC Sep. 2 at 1:45 PM

$STOK https://www.quiverquant.com/news/Biogen%2Band%2BStoke%2BTherapeutics%2BAnnounce%2BThree-Year%2BResults%2BSupporting%2BZorevunersen%27s%2BPromise%2Bfor%2BDravet%2BSyndrome%2BTreatment?utm_source=chatgpt.com

0 · Reply

BioTechHealthX Aug. 28 at 1:13 AM

$STOK Stoke’s zorevunersen looks promising for Dravet syndrome, but with no data until 2027 and only one drug in play, STOK may face a correction. https://biotechhealthx.com/biotech-news/stoke-therapeutics-stok-soars-but-hidden-risks-could-trigger-a-sell-off/

0 · Reply

GlobalMarketBulletin Aug. 28 at 1:04 AM

0 · Reply

stowtrader Aug. 27 at 11:36 PM

$ICCM I bought a position today, lfg and fda approval on deck, let's make money plus I really want this to help breast cancer. 🚀 $STOK

1 · Reply

stowtrader Aug. 27 at 11:33 PM

$STOK i sold around 18 and made a lot. Time to get back in lol.

0 · Reply

Morty752 Aug. 27 at 3:18 PM

$STOK I should have gone all in here when it was $13.

0 · Reply

RunnerSignals Aug. 26 at 9:48 PM

and the comeback kings today $CHGG $TMC $RIOT $STOK $HTZ all hit their lows but bounced back big

0 · Reply

prismmarketview Aug. 25 at 8:38 PM

$STOK and $BIIB presented 3-year data for zorevunersen in Dravet syndrome showing durable seizure reductions and signs of disease modification. With the Phase 3 EMPEROR trial enrolling, this candidate could reshape treatment for a devastating epilepsy disorder. https://prismmarketview.com/stoke-and-biogen-showcase-3-year-data-for-zorevunersen-in-dravet-syndrome-with-signs-of-disease-modification/

0 · Reply

FFGarcia Aug. 25 at 3:56 AM

$STOK Weekly chart. Bullish; first predicted major long-term target is 33.

0 · Reply

Chrisq82 Aug. 22 at 6:33 PM

$STOK bring back January 2021 of $70!!!!!

0 · Reply

TylerDurd3n Aug. 21 at 3:31 PM

$STOK

0 · Reply

Market Cap	1.29B
Revenue (ttm)	36.56M
Net Income (ttm)	-88.98M
EPS (ttm)	N/A
PE Ratio	28.09
Forward PE	79.60
Profit Margin	-243.38%
Debt to Equity Ratio	0.00

Volume	1,030,900
Avg Vol	873,500
Day's Range	N/A - N/A
Shares Out	54.80M
Stochastic %K	80%
Beta	1.14
Analysts	Strong Sell
Price Target	$24.22